Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Mass cytometry identifies distinct CD4+ T cell clusters distinguishing HIV-1-infected patients according to antiretroviral therapy initiation.

Bekele Y, Lakshmikanth T, Chen Y, Mikes J, Nasi A, Petkov S, Hejdeman B, Brodin P, Chiodi F.

JCI Insight. 2019 Feb 7;4(3). pii: 125442. doi: 10.1172/jci.insight.125442. [Epub ahead of print]

2.

Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.

Sörstedt E, Carlander C, Flamholc L, Hejdeman B, Svedhem V, Sönnerborg A, Gisslén M, Yilmaz A.

Int J Antimicrob Agents. 2018 May;51(5):733-738. doi: 10.1016/j.ijantimicag.2018.01.009. Epub 2018 Jan 31.

PMID:
29371105
3.

Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden.

Andersson E, Nordquist A, Esbjörnsson J, Flamholc L, Gisslén M, Hejdeman B, Marrone G, Norrgren H, Svedhem V, Wendahl S, Albert J, Sönnerborg A.

AIDS. 2018 Apr 24;32(7):877-884. doi: 10.1097/QAD.0000000000001763.

PMID:
29369826
4.

Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.

Neogi U, Singh K, Aralaguppe SG, Rogers LC, Njenda DT, Sarafianos SG, Hejdeman B, Sönnerborg A.

AIDS. 2018 Feb 20;32(4):469-476. doi: 10.1097/QAD.0000000000001726.

5.

Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.

Häggblom A, Santacatterina M, Neogi U, Gisslen M, Hejdeman B, Flamholc L, Sönnerborg A.

PLoS One. 2017 Jul 20;12(7):e0180140. doi: 10.1371/journal.pone.0180140. eCollection 2017.

6.

HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014.

Häggblom A, Lindbäck S, Gisslén M, Flamholc L, Hejdeman B, Palmborg A, Leval A, Herweijer E, Valgardsson S, Svedhem V.

PLoS One. 2017 Feb 16;12(2):e0171227. doi: 10.1371/journal.pone.0171227. eCollection 2017.

7.

Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection.

Amu S, Lantto Graham R, Bekele Y, Nasi A, Bengtsson C, Rethi B, Sorial S, Meini G, Zazzi M, Hejdeman B, Chiodi F.

Medicine (Baltimore). 2016 Jun;95(23):e3738. doi: 10.1097/MD.0000000000003738. Erratum in: Medicine (Baltimore). 2016 Jul 18;95(28):e0916.

8.

Increased extrafollicular expression of the B-cell stimulatory molecule CD70 in HIV-1-infected individuals.

Lantto R, Nasi A, Sammicheli S, Amu S, Fievez V, Moutschen M, Pensieroso S, Hejdeman B, Chiodi F, Rethi B.

AIDS. 2015 Sep 10;29(14):1757-66. doi: 10.1097/QAD.0000000000000779.

PMID:
26262581
9.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, Earl PL, Stout RR, Robb ML, Shattock RJ, Biberfeld G, Sandström E, Wahren B.

PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.

10.

Vitamin D status in Well-Controlled Caucasian HIV Patients in Relation to Inflammatory and Metabolic Markers--A Cross-Sectional Cohort Study in Sweden.

Missailidis C, Höijer J, Johansson M, Ekström L, Bratt G, Hejdeman B, Bergman P.

Scand J Immunol. 2015 Jul;82(1):55-62. doi: 10.1111/sji.12299.

11.

Frequency and phenotype of B cell subpopulations in young and aged HIV-1 infected patients receiving ART.

Amu S, Lavy-Shahaf G, Cagigi A, Hejdeman B, Nozza S, Lopalco L, Mehr R, Chiodi F.

Retrovirology. 2014 Sep 11;11:76. doi: 10.1186/s12977-014-0076-x.

12.

T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection.

Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson MA, Michaëlsson J, Lund O, Hejdeman B, Jansson M, Sönnerborg A, Koup RA, Betts MR, Karlsson AC.

PLoS Pathog. 2014 Jul 17;10(7):e1004251. doi: 10.1371/journal.ppat.1004251. eCollection 2014 Jul.

13.

Immunotherapy with an HIV-DNA Vaccine in Children and Adults.

Palma P, Gudmundsdotter L, Finocchi A, Eriksson LE, Mora N, Santilli V, Aquilani A, Manno EC, Zangari P, Romiti ML, Montesano C, Grifoni A, Brave A, Ljungberg K, Blomberg P, Bernardi S, Sandström E, Hejdeman B, Rossi P, Wahren B.

Vaccines (Basel). 2014 Jul 17;2(3):563-80. doi: 10.3390/vaccines2030563.

14.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

15.

Declining HIV-1 prevalence and incidence among Police Officers - a potential cohort for HIV vaccine trials, in Dar es Salaam, Tanzania.

Munseri PJ, Bakari M, Janabi M, Aris E, Aboud S, Hejdeman B, Sandstrom E.

BMC Public Health. 2013 Aug 6;13:722. doi: 10.1186/1471-2458-13-722.

16.

Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness.

Nowroozalizadeh S, Gudmundsdotter L, Hejdeman B, Andersson L, Esbjörnsson J, Medstrand P, Sandström E, Gaines H, Wahren B, Jansson M.

Hum Vaccin Immunother. 2013 Oct;9(10):2103-10. doi: 10.4161/hv.25154. Epub 2013 Jun 4.

17.

Relation of activation-induced deaminase (AID) expression with antibody response to A(H1N1)pdm09 vaccination in HIV-1 infected patients.

Cagigi A, Pensieroso S, Ruffin N, Sammicheli S, Thorstensson R, Pan-Hammarström Q, Hejdeman B, Nilsson A, Chiodi F.

Vaccine. 2013 Apr 26;31(18):2231-7. doi: 10.1016/j.vaccine.2013.03.002. Epub 2013 Mar 14.

PMID:
23499520
18.

B-cell subset alterations and correlated factors in HIV-1 infection.

Pensieroso S, Galli L, Nozza S, Ruffin N, Castagna A, Tambussi G, Hejdeman B, Misciagna D, Riva A, Malnati M, Chiodi F, Scarlatti G.

AIDS. 2013 May 15;27(8):1209-17. doi: 10.1097/QAD.0b013e32835edc47.

PMID:
23343911
19.

Concerted effect of lymphopenia, viraemia and T-cell activation on Fas expression of peripheral B cells in HIV-1-infected patients.

Rethi B, Sammicheli S, Amu S, Pensieroso S, Hejdeman B, Schepis D, Thang PH, Chiodi F.

AIDS. 2013 Jan 14;27(2):155-62. doi: 10.1097/QAD.0b013e32835b8c5e.

PMID:
23238551
20.

Immune activation and increased IL-21R expression are associated with the loss of memory B cells during HIV-1 infection.

Ruffin N, Lantto R, Pensieroso S, Sammicheli S, Hejdeman B, Rethi B, Chiodi F.

J Intern Med. 2012 Nov;272(5):492-503. doi: 10.1111/j.1365-2796.2012.02550.x. Epub 2012 Jun 15.

21.

NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.

Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, Hinkula J, Wahren B, Kärre K, Kent SJ, Berg L.

Viral Immunol. 2011 Oct;24(5):359-68. doi: 10.1089/vim.2011.0025. Epub 2011 Sep 29.

PMID:
21958370
22.

Survival and proliferation of CD28- T cells during HIV-1 infection relate to the amplitude of viral replication.

Vivar N, Ruffin N, Sammicheli S, Hejdeman B, Rethi B, Chiodi F.

J Infect Dis. 2011 Jun 1;203(11):1658-67. doi: 10.1093/infdis/jir156.

PMID:
21592996
23.

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.

Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, Buttò S, Gaines H, Imami N, Gotch F, Lori F, Lisziewicz J, Sandström E, Hejdeman B.

Vaccine. 2011 Jul 26;29(33):5558-66. doi: 10.1016/j.vaccine.2011.01.064. Epub 2011 Feb 5.

PMID:
21300092
24.

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation.

Bråve A, Gudmundsdotter L, Sandström E, Haller BK, Hallengärd D, Maltais AK, King AD, Stout RR, Blomberg P, Höglund U, Hejdeman B, Biberfeld G, Wahren B.

Vaccine. 2010 Nov 29;28(51):8203-9. doi: 10.1016/j.vaccine.2010.08.108. Epub 2010 Oct 15.

PMID:
20951666
25.

NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients.

Johansson SE, Hejdeman B, Hinkula J, Johansson MH, Romagné F, Wahren B, Wagtmann NR, Kärre K, Berg L.

Clin Immunol. 2010 Feb;134(2):158-68. doi: 10.1016/j.clim.2009.10.001. Epub 2009 Nov 1.

PMID:
19880352
26.

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B.

Vaccine. 2009 Jul 16;27(33):4468-74. doi: 10.1016/j.vaccine.2009.05.018. Epub 2009 May 29.

27.

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G; HIV Immunogenicity Study 01/02 Team.

J Infect Dis. 2008 Nov 15;198(10):1482-90. doi: 10.1086/592507.

28.

Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles.

Gudmundsdotter L, Bernasconi D, Hejdeman B, Sandstrom E, Alaeus A, Lidman K, Ensoli B, Wahren B, Buttò S.

Vaccine. 2008 Sep 19;26(40):5182-7. doi: 10.1016/j.vaccine.2008.03.094. Epub 2008 Apr 22.

PMID:
18479789
29.

Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization.

Gudmundsdotter L, Boström AC, Burton C, Rosignoli G, Sandström E, Hejdeman B, Wahren B, Imami N, Gotch F.

Vaccine. 2008 Sep 19;26(40):5107-10. doi: 10.1016/j.vaccine.2008.03.063. Epub 2008 Apr 14.

PMID:
18455841
30.

Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects.

Nilsson C, Aboud S, Karlén K, Hejdeman B, Urassa W, Biberfeld G.

Clin Vaccine Immunol. 2008 Apr;15(4):585-9. doi: 10.1128/CVI.00161-07. Epub 2008 Feb 20.

31.

Therapeutic immunization for HIV.

Gudmundsdotter L, Sjödin A, Boström AC, Hejdeman B, Theve-Palm R, Alaeus A, Lidman K, Wahren B.

Springer Semin Immunopathol. 2006 Nov;28(3):221-30. Epub 2006 Oct 10. Review.

PMID:
17031650
32.

Antiretroviral therapy does not induce HIV type 1-specific neutralizing activity against autologous HIV type 1 isolates.

Devito C, Hejdeman B, Albert J, Broliden K, Hinkula J.

AIDS Res Hum Retroviruses. 2006 Sep;22(9):908-11.

PMID:
16989617
33.

Human immunodeficiency virus-type 1 specific cellular immunity in chronic infected patients on prolonged highly active antiretroviral treatment and on structured treatment interruption.

Matsuda R, Boström AC, Fredriksson M, Fredriksson EL, Bratt G, Hejdeman B, Sandström E, Okuda K, Wahren B.

Microbiol Immunol. 2006;50(8):629-35.

34.

[Sexually transmitted infections increase the risk of HIV. A survey among men who have sex with men shows a strong connection].

Bratt G, Hejdeman B.

Lakartidningen. 2006 May 3-9;103(18):1438-9. Swedish. No abstract available.

PMID:
16729457
35.

Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection.

Titanji K, De Milito A, Cagigi A, Thorstensson R, Grützmeier S, Atlas A, Hejdeman B, Kroon FP, Lopalco L, Nilsson A, Chiodi F.

Blood. 2006 Sep 1;108(5):1580-7. Epub 2006 Apr 27.

PMID:
16645169
36.

A nonsense mutation (428G-->A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection.

Kindberg E, Hejdeman B, Bratt G, Wahren B, Lindblom B, Hinkula J, Svensson L.

AIDS. 2006 Mar 21;20(5):685-9.

PMID:
16514298
37.

The rationale behind a vaccine based on multiple HIV antigens.

Rollman E, Bråve A, Boberg A, Gudmundsdotter L, Engström G, Isaguliants M, Ljungberg K, Lundgren B, Blomberg P, Hinkula J, Hejdeman B, Sandström E, Liu M, Wahren B.

Microbes Infect. 2005 Nov;7(14):1414-23. Epub 2005 Sep 29.

PMID:
16257558
38.

DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy.

Hejdeman B, Boström AC, Matsuda R, Calarota S, Lenkei R, Fredriksson EL, Sandström E, Bratt G, Wahren B.

AIDS Res Hum Retroviruses. 2004 Aug;20(8):860-70.

PMID:
15320990
39.

Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).

Boström AC, Hejdeman B, Matsuda R, Fredriksson M, Fredriksson EL, Bratt G, Sandström E, Wahren B.

Vaccine. 2004 Apr 16;22(13-14):1683-91.

PMID:
15068851
40.

The reverse transcriptase (RT) mutation V118I is associated with virologic failure on abacavir-based antiretroviral treatment (ART) in HIV-1 infection.

Säberg P, Koppel K, Bratt G, Fredriksson EL, Hejdeman B, Sitbon G, Sandström E.

Scand J Infect Dis. 2004;36(1):40-5.

PMID:
15000558
42.

HIV subtypes and recombination strains--strategies for induction of immune responses in man.

Wahren B, Ljungberg K, Rollman E, Levi M, Zuber B, Kjerrström Zuber A, Hinkula J, Leandersson AC, Calarota S, Hejdeman B, Bratt G, Sandström E.

Vaccine. 2002 May 6;20(15):1988-93. Review.

PMID:
11983260
43.

[HIV, gonorrhea, chlamydia and syphilis are increasing among homosexual men].

Karlsson A, Hejdeman B, Pernetun T, Sandström E.

Lakartidningen. 2001 Apr 11;98(15):1793-5. Swedish.

PMID:
11374006
44.

Human natural killer cells in asymptomatic human immunodeficiency virus-1 infection.

Hultström AL, Hejdeman B, Leandersson AC, Bratt G, Carbone E, Wahren B.

Intervirology. 2000;43(4-6):294-301.

PMID:
11251385
45.

Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection.

Hejdeman B, Lenkei R, Leandersson AC, Hultström AL, Wahren B, Sandström E, Bratt G.

AIDS Res Hum Retroviruses. 2001 Mar 1;17(4):277-86.

PMID:
11242515
46.

Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.

O'Meara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J.

J Clin Microbiol. 2001 Feb;39(2):464-73.

47.

High plasma levels of soluble fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy.

De Milito A, Hejdeman B, Albert J, Aleman S, Sönnerborg A, Zazzi M, Chiodi F.

AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1379-84.

PMID:
11018857
48.

Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.

Van Vaerenbergh K, Van Laethem K, Albert J, Boucher CA, Clotet B, Floridia M, Gerstoft J, Hejdeman B, Nielsen C, Pannecouque C, Perrin L, Pirillo MF, Ruiz L, Schmit JC, Schneider F, Schoolmeester A, Schuurman R, Stellbrink HJ, Stuyver L, Van Lunzen J, Van Remoortel B, Van Wijngaerden E, Vella S, Witvrouw M, Yerly S, De Clercq E, Destmyer J, Vandamme AM.

Antimicrob Agents Chemother. 2000 Aug;44(8):2109-17.

49.

CMV PCR in leucocytes as an early marker for the development of CMV disease in AIDS patients.

Quarner H, Grützmeier S, Lewensohn-Fuchs I, Hejdeman B, Sandström E, Ehrnst A.

Scand J Infect Dis Suppl. 1995;99:94-5.

PMID:
8668950

Supplemental Content

Loading ...
Support Center